Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Accepted 2023-03-07 00:00:00 ET · period of report 2023-03-03 · accession 0001209191-23-016712 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-03-07 | 2023-03-04+ | TEVA | Kalif Eliyahu Sharon | EVP, CFO | M - OptEx | — | +54.9K | 134.3K | +69% | — |
| D | 2023-03-07 | 2023-03-03 | TEVA | Kalif Eliyahu Sharon | EVP, CFO | A - Grant | $0.00 | +199.2K | 199.2K | New | $0 |
| DM | 2023-03-07 | 2023-03-04+ | TEVA | Kalif Eliyahu Sharon | EVP, CFO | M - OptEx | $0.00 | -54.9K | 100.5K | -35% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-03-04 | M | A | 33,512 | — | 112,900 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| 2 | Common | Ordinary Shares | 2023-03-05 | M | A | 21,387 | — | 134,287 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| 3 | Derivative | Restricted Share Units | 2023-03-03 | A | A | 199,202 | $0.00 | 199,202 | D | — · — to — | 199,202 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F3) Restricted share units were granted on March 3, 2023, with 49,800 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 49,802 vesting on March 3, 2027. |
| 4 | Derivative | Restricted Share Units | 2023-03-05 | M | D | 21,387 | $0.00 | 42,777 | D | — · — to — | 21,387 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F5) Restricted share units were granted on March 5, 2021, with 21,387 vested on each of March 5, 2022 and March 5, 2023, 21,387 vesting on March 5, 2024, and 21,390 vesting on March 5, 2025. |
| 5 | Derivative | Restricted Share Units | 2023-03-04 | M | D | 33,512 | $0.00 | 100,536 | D | — · — to — | 33,512 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F4) Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026. |